SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following its recent FDA approval of NEREUS (tradipitant), marking the first new motion sickness drug in nearly 40 years. The community is buzzing with excitement over its significant potential to address GLP-1 induced nausea and vomiting, fueling widespread speculation about a potential buyout by major pharma and a substantial re-rating of the stock's valuation. Investors are largely bullish, anticipating further upside driven by this approval and additional pipeline catalysts.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust is experiencing significant volatility amid intensified speculation around tightening Chinese silver export restrictions and multiple CME margin hikes. Community sentiment is deeply divided, with many anticipating a major short squeeze driven by industrial demand and geopolitical supply concerns. Others warn of a historical "pump and dump" pattern and the impact of increased margin requirements, creating a high-stakes environment as participants weigh physical scarcity against paper market pressures.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as its stock experiences significant declines to fresh lows, sparking intense debate among investors. The community is actively discussing major broker restrictions on online share purchases and perceived market manipulation, alongside upcoming options expiry for potential volatility. Bulls, pointing to strong fundamentals and early SOX compliance, remain confident in a rebound, while skeptics express frustration over management's communication and unmet project updates.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as China's confirmed extension of EV trade-in subsidies into 2026 and new mandatory energy consumption standards provide a significant sector tailwind. This is fueling community optimism about the company's strong Q4 sales and potential profitability, driven by the CEO's upbeat forecast and recent milestones like 40,000 ES8 deliveries and 96 million battery swaps, with many believing the stock is undervalued due to perceived market manipulation and the long-term advantages of its battery swap technology.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire (RDW) is drawing significant attention after securing an eight-figure contract for spacecraft docking systems, amplifying bullish sentiment for its space infrastructure and defense technologies. The community is actively discussing a high short interest and potential for a squeeze, viewing RDW as a key player poised for growth in the accelerating global "space race" with its diverse offerings in drones and in-space manufacturing.

Utopia is a digital paradise designed to reward every step of a user's journey. It is a world where community and cutting-edge technology converge to foster unprecedented freedom, creativity, and tangible value.At the heart of Utopia lies a living, breathing ecosystem where user engagement directly fuels the economy.Participants guide the Utopia girl on her path, drawing her closer to the world's core. With each step, a user's influence grows, as do their potential BNB rewards. Utopia is built on the principle that exploration and active participation should be directly linked to prosperity.The path is for each user to shape, and every discovery brings them closer to the center of it all.

Utopia

Utopia Crypto is attracting considerable buzz after its debut on a major exchange, with the community actively anticipating substantial growth for this digital world platform offering token rewards. Many within the community view it as a hidden gem, believing it is significantly undervalued and poised for considerable upward movement.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics Holdings is trending due to its proposed business combination with Applied Digital Cloud to form ChronoScale Corporation, an entity focused on AI-accelerated computing infrastructure. This catalyst has sparked intense community discussion, with many anticipating significant upside from the AI sector and low float dynamics, while a strong counter-narrative raises concerns about potential shareholder dilution and the merger's unfavorable terms for existing EKSO holders.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining Corp. is trending as it evaluates an IPO for its North American gold assets and has successfully settled disputes in Mali, aiming to unlock substantial shareholder value. These strategic initiatives, coupled with an activist stake by Elliott Management and strong financial results featuring increased dividends and share buybacks, are generating significant investor interest amidst a bullish outlook for precious metals and copper.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa (V) is a focal point in market discussions after reporting strong earnings and raising its dividend, underscoring its consistent performance as a global payments leader. The company's strategic moves into stablecoin settlements and AI-driven commerce are key talking points, with investors debating its continued growth potential amidst robust network expansion and recent market volatility.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx is a major trending topic after its setrusumab drug failed to meet primary endpoints in Phase 3 trials for osteogenesis imperfecta, leading to a sharp market reaction. While some view the sell-off as an overreaction, highlighting the company's existing portfolio of approved therapies and other pipeline assets, the community is actively assessing the implications for its future growth trajectory. The focus is now on how these developments reshape the outlook for its broader rare disease pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MBX Biosciences (NASDAQ:MBX) Stock Price Down 5.8% - Here's What Happened

MBX Biosciences (NASDAQ:MBX) Stock Price Down 5.8% - Should You Sell...

MBX Biosciences (NASDAQ:MBX) Reaches New 12-Month High - Still a Buy?

MBX Biosciences (NASDAQ:MBX) Hits New 12-Month High - What's Next...

MBX Biosciences (NASDAQ:MBX) Stock Price Up 10.8% - Still a Buy?

MBX Biosciences (NASDAQ:MBX) Stock Price Up 10.8% - What's Next...

MBX Biosciences (NASDAQ:MBX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of MBX Biosciences from a "sell" rating to a "hold" rating in a research note on Sunday...

EcoR1 Capital LLC Lowers Holdings in MBX Biosciences, Inc. $MBX

EcoR1 Capital LLC trimmed its holdings in MBX Biosciences, Inc. (NASDAQ:MBX - Free Report) by 8.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission...

MBX Biosciences (NASDAQ:MBX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut MBX Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday...

Walleye Capital LLC Increases Stock Holdings in MBX Biosciences, Inc. $MBX

Walleye Capital LLC grew its stake in MBX Biosciences, Inc. (NASDAQ:MBX - Free Report) by 116.5% during the second quarter, according to the company in its most recent disclosure with the Securities...

MBX Biosciences, Inc. $MBX Stake Increased by Stempoint Capital LP

Stempoint Capital LP lifted its stake in MBX Biosciences, Inc. (NASDAQ:MBX - Free Report) by 46.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange...

MBX Biosciences (NASDAQ:MBX) Shares Down 5.6% - Should You Sell?

MBX Biosciences (NASDAQ:MBX) Stock Price Down 5.6% - Here's Why...

Resolute Capital Asset Partners LLC Acquires New Position in MBX Biosciences, Inc. $MBX

Resolute Capital Asset Partners LLC acquired a new position in shares of MBX Biosciences, Inc. (NASDAQ:MBX - Free Report) during the 2nd quarter, according to the company in its most recent filing...

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Current Price	$30.90
Prev Close	$31.07
Open	$31.12
Dividend Yield	0.00%
50-Day Moving Average	$26.45
Beta	1.73
Avg. Volume	691,468.63
PE Ratio	-12.91

52-Week High	$35.55
52-Week Low	$4.81
Market Capitalization	$1.4B
EPS (Annual)	-$1.85
Price to Book	3.57
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MBX
MBX Biosciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MBX News

MBXMBX Biosciences Inc.